| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.42 | 0.01 |
| mRNA | BIBW2992 | FIMM | pan-cancer | AAC | 0.38 | 0.01 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.41 | 0.02 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | 0.16 | 0.02 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |